Roche under pressure in US as Amgen/Allergan launch US cance...

Amgen and Allergan have launched their cut-price biosimilar competitors to two big-selling cancer drugs from Roche in the US.

German court blocks Sanofi's cholesterol drug after Amgen la...

Amgen has lived up to its litigious reputation after it successfully persuaded a German court to uphold a patent blocking Sanofi from marketing its rival injected cholesterol drug in the co

Novartis and Amgen axe BACE drug for Alzheimer's

Another Alzheimer’s disease drug has been axed after Novartis, Amgen and the Banner Alzheimer’s Institute decided to end two pivotal studies involving a medicine targeting BACE.

CHMP says no to Amgen’s osteoporosis drug Evenity

Three drugmakers challenge Trump’s price disclosure ruling

Amgen, Merck & Co and Eli Lilly have launched a legal challenge to a new rule that will require them to disclose medicine list prices in direct-to-consumer (DTC) television ads.

FDA approves Herceptin biosimilar as US patent expires

The FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer blockbuster’s patent expiry.